Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1399-1403

  Sandoo, Aamer ^a,b   Dimitroulas, Theodoros ^a   Toms, Tracey E ^a,c   Hodson, James ^d   Veldhuijzen van Zanten, Jet J C S ^a,b   Smith, Jacqueline P ^a   Kitas, George D ^a,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ADMA; Anti TNF treatment; Cardiovascular disease; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; FIBRINOGEN; INFLIXIMAB; N(G),N(G) DIMETHYLARGININE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARGININE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868303979     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.092     Document Type: Article

References (33)

1. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46:862-873.
2. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14.
3. Gokce N., Keaney J.F., Hunter L.M., Watkins M.T., Nedeljkovic Z.S., Menzoian J.O., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patient with peripheral vascular disease. J Am Coll Cardiol 2003, 41:1769-1775.
4. Vaudo G., Marchesi S., Gerli R., Allegrucci R., Giordano A., Siepi D., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35.
5. Bergholm R., Leirisalo-Repo M., Vehkavaara S., Mäkimattila S., Taskinen M.R., Yki-Järvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637-1641.
6. Stevens R.J., Douglas K.M., Saratzis A.N., Kitas G.D. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005, 7:1-24.
7. Warrington K.J. Anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: hitting two birds with one stone?. Arthritis Rheum 2004, 51:309-310.
8. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alén J., Hørslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
9. De Gennaro Colonna V., Bianchi M., Pascale V., Ferrario P., Morelli F., et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009, 15:RA9.
10. Wanby P., Teerlink T., Brudin L., Brattström L., Nilsson I., Palmqvist P., et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006, 185:271-277.
11. Nishiyama Y., Ueda M., Katsura K.I., Otsuka T., Abe A., Nagayama H., et al. Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke. J Neurol Sci 2010, 290:12-15.
12. Sandoo A., Dimitroulas T., Veldhuijzen van Zanten Jet J.J.C.S., Smith Jacqueline P., Metsios George S., Nightingale Peter, et al. Lack of association between asymmetric dimethylarginine and invivo microvascular or macrovascular endothelial function in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012, 30:388-396.
13. Surdacki A., Martens-Lobenhoffer J., Wloch A., Marewicz E., Rakowski T., Wieczorek-Surdacka E., et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007, 56:809-819.
14. Turiel M., Atzeni F., Tomasoni L., de Portu S., Delfino L., Bodini B.D., et al. Non invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 2009, 48:834-839.
15. National Institute for Health and Clinical Excellence Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (final appraisal determination) (7 April 20011, date last accessed). http://guidance.nice.org.uk/download.aspx?o%BC388554.
16. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
17. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients withrheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
18. Kirwan J.R., Reeback J.S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986, 25:206-209.
19. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619. [Reynolds:].
20. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., Minhas R., Sheikh A., et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008, 3361475-3361482. [QRisk2:].
21. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
22. endothelialGalarraga B., Khan F., Kumar P., Pullar T., Belch J.J. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009, 48:1418-1423.
23. Datta D., Ferrell W.R., Sturrock R.D., Jadhav S.T., Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007, 192:391-395.
24. Sidiropoulos P.I., Siakka P., Pagonidis K., Raptopoulou A., Kritikos H., Tsetis D., et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009, 38:6-10.
25. Van Doornum S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005, 44:1428-1432.
26. Södergren A., Karp K., Boman K., Eriksson C., Lundström E., Smedby T., et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010, 12:R158.
27. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450.
28. Sandoo A., Veldhuijzen van Zanten J.J., Metsios G.S., Carroll D., Kitas G.D. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology 2011, 50:2125-2139.
29. Turiel M., Tomasoni L., Sitia S., Cicala S., Gianturco L., Ricci C., et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010, 10:1-12.
30. Peters M.J., van Sijl A.M., Voskuyl A.E., Sattar N., Smulders Y.M., Nurmohamed M.T. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2012, 18:1502-1511.
31. Crowson C.S., Myasoedova E., Roger V.L., et al. Does the Framingham Score underestimate cardiovascular risk in rheumatoid arthritis? [Abstract]. Arthritis Rheum 2009, 60:S264.
32. Antoniades C., Demosthenous M., Tousoulis D., Antonopoulos A.S., Vlachopoulos C., Toutouza M., et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011, 58:93-98.
33. Kwaśny-Krochin B., Głuszko P., Undas A. Plasma asymmetric dimethyl-L-arginine (ADMA) in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn 2012, 122:270-276.